ARCT Jun 2024 50.000 put
| Previous close | 14.00 |
| Open | 14.00 |
| Bid | 17.00 |
| Ask | 18.50 |
| Strike | 50.00 |
| Expiry date | 2024-06-21 |
| Day's range | 14.00 - 14.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 10 |
Business WireArcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
SAN DIEGO, June 07, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today presented Phase 1 results in healthy volunteers and Phase 1b interim data in people with CF for ARCT-032, an inhaled investigational mRNA therapeutic, at the 47th European Cystic Fibrosis Conference in G
GuruFocus.comInsider Sale: Chief Scientific Officer & COO Pad Chivukula Sells 26,000 Shares of Arcturus ...
Chief Scientific Officer & Chief Operating Officer Pad Chivukula of Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) sold 26,000 shares of the company on June 3, 2024, as reported in a recent SEC Filing.
Business WireArcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
SAN DIEGO, May 28, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced Arcturus will be presenting Phase 1 results in healthy volunteers and new Phase 1b interim data in CF patients for ARCT-032, an inhaled investigational mRNA therapeutic to tr
